Daxor (NASDAQ:DXR) Stock Price Up 0.8% – Should You Buy?

Daxor Co. (NASDAQ:DXR)’s stock price traded up 0.8% during trading on Wednesday . The company traded as high as $7.75 and last traded at $7.69. 24,226 shares were traded during mid-day trading, an increase of 221% from the average session volume of 7,537 shares. The stock had previously closed at $7.63.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets upped their price objective on Daxor from $24.50 to $24.75 and gave the company a “buy” rating in a research note on Monday, September 9th.

Daxor Trading Up 2.9 %

The stock’s fifty day simple moving average is $8.76 and its two-hundred day simple moving average is $8.88.

Institutional Trading of Daxor

An institutional investor recently raised its position in Daxor stock. Keyes Stange & Wooten Wealth Management LLC lifted its holdings in shares of Daxor Co. (NASDAQ:DXR) by 34.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,612 shares of the company’s stock after buying an additional 3,771 shares during the period. Keyes Stange & Wooten Wealth Management LLC owned approximately 0.30% of Daxor worth $126,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 1.34% of the company’s stock.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.